Inlyta

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
28-09-2021
Ciri produk Ciri produk (SPC)
28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
21-08-2015

Bahan aktif:

axitinib

Boleh didapati daripada:

Pfizer Europe MA EEIG 

Kod ATC:

L01EK01

INN (Nama Antarabangsa):

axitinib

Kumpulan terapeutik:

Protein kinase inhibitors

Kawasan terapeutik:

Carcinoma, Renal Cell

Tanda-tanda terapeutik:

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

Ringkasan produk:

Revision: 14

Status kebenaran:

Authorised

Tarikh kebenaran:

2012-09-03

Risalah maklumat

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
INLYTA 1 MG FILM-COATED TABLETS
INLYTA 3 MG FILM-COATED TABLETS
INLYTA 5 MG FILM-COATED TABLETS
INLYTA 7 MG FILM-COATED TABLETS
axitinib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Inlyta is and what it is used for
2.
What you need to know before you take Inlyta
3.
How to take Inlyta
4.
Possible side effects
5.
How to store Inlyta
6.
Contents of the pack and other information
1.
WHAT INLYTA IS AND WHAT IT IS USED FOR
Inlyta is a medicine containing the active substance axitinib.
Axitinib reduces the blood supply to the
tumour and slows down the growth of cancer.
Inlyta is indicated for the treatment of advanced kidney cancer
(advanced renal cell carcinoma) in
adults, when another medicine (called sunitinib or a cytokine) is no
longer stopping disease from
progressing.
If you have any questions about how this medicine works or why this
medicine has been prescribed
for you, ask your doctor.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE INLYTA
DO NOT TAKE INLYTA:
If you are allergic to axitinib or any of the other ingredients of
this medicine (listed in section 6).
If you think you may be allergic, ask your doctor for advice.
WARNINGS AND PRECAUTIONS
TALK TO YOUR DOCTOR OR NURSE BEFORE TAKING INLYTA
•
IF YOU HAVE HIGH BLOOD PRESSURE.
Inlyta can raise your blood pressure. It is important to check your
blood pressure before you
take this medicine, and regularly while you are taking it. If you have
high blood pressure
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Inlyta 1 mg film-coated tablets
Inlyta 3 mg film-coated tablets
Inlyta 5 mg film-coated tablets
Inlyta 7 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Inlyta 1 mg film-coated tablets
Each film-coated tablet contains 1 mg of axitinib.
_ _
Inlyta 3 mg film-coated tablets
Each film-coated tablet contains 3 mg of axitinib.
Inlyta 5 mg film-coated tablets
Each film-coated tablet contains 5 mg of axitinib.
Inlyta 7 mg film-coated tablets
Each film-coated tablet contains 7 mg of axitinib.
_ _
Excipients with known effect
_Inlyta 1 mg film-coated tablet _
Each film-coated tablet contains 33.6 mg of lactose monohydrate.
_Inlyta 3 mg film-coated tablet_
Each film-coated tablet contains 35.3 mg of lactose monohydrate.
_Inlyta 5 mg film-coated tablet _
Each film-coated tablet contains 58.8 mg of lactose monohydrate.
_Inlyta 7 mg film-coated tablet _
Each film-coated tablet contains 82.3 mg of lactose monohydrate.
_ _
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Inlyta 1 mg film-coated tablets
Red oval film-coated tablet debossed with “Pfizer” on one side and
“1 XNB” on the other.
Inlyta 3 mg film-coated tablets
Red round film-coated tablet debossed with “Pfizer” on one side
and “3 XNB” on the other.
Inlyta 5 mg film-coated tablets
Red triangular film-coated tablet debossed with “Pfizer” on one
side and “5 XNB” on the other.
Inlyta 7 mg film-coated tablets
Red diamond shaped film-coated tablet debossed with “Pfizer” on
one side and “7 XNB” on the other.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Inlyta is indicated for the treatment of adult patients with advanced
renal cell carcinoma (RCC) after
failure of prior treatment with sunitinib or a cytokine.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Treatment with Inlyta should be conducted by a physician experienced
in the use of anticancer
therapies.
Posology
_ _
The recommended
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 28-09-2021
Ciri produk Ciri produk Bulgaria 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 21-08-2015
Risalah maklumat Risalah maklumat Sepanyol 28-09-2021
Ciri produk Ciri produk Sepanyol 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 21-08-2015
Risalah maklumat Risalah maklumat Czech 28-09-2021
Ciri produk Ciri produk Czech 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 21-08-2015
Risalah maklumat Risalah maklumat Denmark 28-09-2021
Ciri produk Ciri produk Denmark 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 21-08-2015
Risalah maklumat Risalah maklumat Jerman 28-09-2021
Ciri produk Ciri produk Jerman 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 21-08-2015
Risalah maklumat Risalah maklumat Estonia 28-09-2021
Ciri produk Ciri produk Estonia 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 21-08-2015
Risalah maklumat Risalah maklumat Greek 28-09-2021
Ciri produk Ciri produk Greek 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 21-08-2015
Risalah maklumat Risalah maklumat Perancis 28-09-2021
Ciri produk Ciri produk Perancis 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 21-08-2015
Risalah maklumat Risalah maklumat Itali 28-09-2021
Ciri produk Ciri produk Itali 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 21-08-2015
Risalah maklumat Risalah maklumat Latvia 28-09-2021
Ciri produk Ciri produk Latvia 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 21-08-2015
Risalah maklumat Risalah maklumat Lithuania 28-09-2021
Ciri produk Ciri produk Lithuania 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 21-08-2015
Risalah maklumat Risalah maklumat Hungary 28-09-2021
Ciri produk Ciri produk Hungary 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 21-08-2015
Risalah maklumat Risalah maklumat Malta 28-09-2021
Ciri produk Ciri produk Malta 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 21-08-2015
Risalah maklumat Risalah maklumat Belanda 28-09-2021
Ciri produk Ciri produk Belanda 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 21-08-2015
Risalah maklumat Risalah maklumat Poland 28-09-2021
Ciri produk Ciri produk Poland 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 21-08-2015
Risalah maklumat Risalah maklumat Portugis 28-09-2021
Ciri produk Ciri produk Portugis 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 21-08-2015
Risalah maklumat Risalah maklumat Romania 28-09-2021
Ciri produk Ciri produk Romania 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 21-08-2015
Risalah maklumat Risalah maklumat Slovak 28-09-2021
Ciri produk Ciri produk Slovak 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 21-08-2015
Risalah maklumat Risalah maklumat Slovenia 28-09-2021
Ciri produk Ciri produk Slovenia 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 21-08-2015
Risalah maklumat Risalah maklumat Finland 28-09-2021
Ciri produk Ciri produk Finland 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 21-08-2015
Risalah maklumat Risalah maklumat Sweden 28-09-2021
Ciri produk Ciri produk Sweden 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 21-08-2015
Risalah maklumat Risalah maklumat Norway 28-09-2021
Ciri produk Ciri produk Norway 28-09-2021
Risalah maklumat Risalah maklumat Iceland 28-09-2021
Ciri produk Ciri produk Iceland 28-09-2021
Risalah maklumat Risalah maklumat Croat 28-09-2021
Ciri produk Ciri produk Croat 28-09-2021
Laporan Penilaian Awam Laporan Penilaian Awam Croat 21-08-2015

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen